Arch Biopartners Inc
XTSX:ARCH
Arch Biopartners Inc
Research & Development
Arch Biopartners Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Research & Development
-CA$639.6k
|
CAGR 3-Years
38%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-16%
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Research & Development
-$167.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Research & Development
-CA$531.2k
|
CAGR 3-Years
-112%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-8%
|
|
Arch Biopartners Inc
Glance View
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
See Also
What is Arch Biopartners Inc's Research & Development?
Research & Development
-639.6k
CAD
Based on the financial report for Jun 30, 2025, Arch Biopartners Inc's Research & Development amounts to -639.6k CAD.
What is Arch Biopartners Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-16%
Over the last year, the Research & Development growth was 88%. The average annual Research & Development growth rates for Arch Biopartners Inc have been 38% over the past three years , 13% over the past five years , and -16% over the past ten years .
